To include your compound in the COVID-19 Resource Center, submit it here.

Cigna eases burden of high cost gene therapies; plan doesn’t account for lack of benefit

As the Medicaid best price rule continues to stymie attempts to move beyond one-time payments for gene therapies, some payers and pharmacy benefit managers are working to soften the blow for their clients and patients. A new model announced by Cigna would allow employers to opt into a new benefit design that would spread the costs to the employer out over time, but does not address what happens when and if the

Read the full 721 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE